CAN10
Inflammatory/Autoimmune Diseases
Phase I (Completed)Acquired by Partner
Key Facts
Indication
Inflammatory/Autoimmune Diseases
Phase
Phase I (Completed)
Status
Acquired by Partner
Company
About Cantargia
Cantargia is a Nasdaq Stockholm-listed biotech focused on translating foundational research on the IL1RAP target into novel antibody therapies for cancer and inflammatory diseases. Its strategy centers on in-house development of candidates like nadunolimab (CAN04) to key value inflection points, followed by strategic partnerships for later-stage development and commercialization, as validated by the 2025 acquisition of its CAN10 program by Otsuka Pharmaceutical. The company's proprietary CANxx platform generates antibodies with a unique dual mechanism of action, positioning it to address significant unmet medical needs across multiple therapeutic areas.
View full company profileTherapeutic Areas
Other Inflammatory/Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| BionicMimics™ Platform | Scinai Immunotherapeutics | Discovery |
| Undisclosed Immunometabolism Program(s) | Inapill | Preclinical |
| NAV-242 | Navigator Medicines | Phase 1 |
| A2AR PAM | Adoram Therapeutics | Hit-to-Lead |
| CAN14 | Cantargia | Preclinical |